DYRKs-IN-2
DYRKs-IN-2 (Example 132) is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 1386980-04-6
- Formula: C32H38ClN9O3
- Molecular Weight:632.16
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-12277
AZ191DYRK1B Inhibitor -
HY-105309
GSK-626616DYRK3 Inhibitor -
HY-13455
LDN-192960Haspin Inhibitor -
HY-12838
RO5454948Dyrk Inhibitor -
HY-117391
AZ-Dyrk1B-33Dyrk1B Kinase Inhibitor -
HY-13455A
LDN-192960 hydrochlorideHaspin Inhibitor -
HY-128758A
DYRKs-IN-1 hydrochlorideDYRKs Inhibitor -
HY-105309R
GSK-626616 (Standard)Reference Standard -
HY-128758
DYRKs-IN-1DYRKs Inhibitor
Biological Activity
Description
IC50 & Target
IC50: 30.6 nM (DYRK1B) and 12.8 nM (DYRK1A)[2]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SW-620 | EC50 |
0.18 μM
Compound: 27
|
Cytotoxicity against human SW620 cells
Cytotoxicity against human SW620 cells
|
[PMID: 24239188] |
In Vitro
DYRKs-IN-2 (Example 132) has an EC50 of 22.8 nM for SW620 cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1386980-04-6
-
Molecular Weight 632.16
-
Formula C32H38ClN9O3
-
SMILES
O=C(C1=CC2=CN=C(NCCCN3CCN(C)CC3)N=C2NC1=O)NC4=CC(C(NC(C5=CC=CC=C5)CCN)=O)=CC=C4Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DYRKs-IN-2 Related Classifications
HY-128759 Related Classifications
Powered by Bioz